Conduction disorders after transcatheter aortic valve implantation: A comparison between SAPIEN 3 and SAPIEN 3 Ultra balloon-expandable valves.
TAVI
aortic stenosis
conduction disorders
conduction disorders in new-generation balloon-expandable valves TAVI
pacemaker
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
04
2022
accepted:
30
09
2022
entrez:
21
11
2022
pubmed:
22
11
2022
medline:
22
11
2022
Statut:
epublish
Résumé
Conduction disorders (CD) are the most common complications after Transcatheter Aortic Valve Implantation (TAVI). The last generation of Edwards balloon expandable valves, the SAPIEN 3 Ultra (S3U), is provided with an external sealing skirt that aims to further reduce paravalvular leakage (PVL) compared to SAPIEN 3 (S3) and could potentially lead to higher CD rate. We sought to investigate the rate of new-onset CD in patients undergoing TAVI with the S3 or S3U valve. We included 582 consecutive patients undergoing TAVI in a single high-volume Center. Patients with previously implanted pacemaker and Valve in valve procedures were excluded. CD rate was evaluated early after implantation and at discharge. No significant difference in the overall CD rate was found between S3 and S3U patients both immediately after the procedure (S3 45.5% vs. S3U 41.8%, No significant difference in the rate of CD, including the need for PPM implantation, was found in patients undergoing TAVI with the S3 compared to S3U. Moreover, S3U significantly reduced the PVL rate.
Sections du résumé
Background
UNASSIGNED
Conduction disorders (CD) are the most common complications after Transcatheter Aortic Valve Implantation (TAVI). The last generation of Edwards balloon expandable valves, the SAPIEN 3 Ultra (S3U), is provided with an external sealing skirt that aims to further reduce paravalvular leakage (PVL) compared to SAPIEN 3 (S3) and could potentially lead to higher CD rate. We sought to investigate the rate of new-onset CD in patients undergoing TAVI with the S3 or S3U valve.
Methods
UNASSIGNED
We included 582 consecutive patients undergoing TAVI in a single high-volume Center. Patients with previously implanted pacemaker and Valve in valve procedures were excluded. CD rate was evaluated early after implantation and at discharge.
Results
UNASSIGNED
No significant difference in the overall CD rate was found between S3 and S3U patients both immediately after the procedure (S3 45.5% vs. S3U 41.8%,
Conclusion
UNASSIGNED
No significant difference in the rate of CD, including the need for PPM implantation, was found in patients undergoing TAVI with the S3 compared to S3U. Moreover, S3U significantly reduced the PVL rate.
Identifiants
pubmed: 36407470
doi: 10.3389/fcvm.2022.922696
pmc: PMC9666421
doi:
Types de publication
Journal Article
Langues
eng
Pagination
922696Informations de copyright
Copyright © 2022 Monizzi, Olivares, Makmur, Fabbiocchi, Grancini, Mastrangelo, Ferrari, Galli, Montorsi and Bartorelli.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Am Coll Cardiol. 2012 Oct 30;60(18):1743-52
pubmed: 23040577
Am J Cardiol. 2011 Mar 1;107(5):747-54
pubmed: 21247519
Eur Heart J. 2021 May 14;42(19):1825-1857
pubmed: 33871579
EuroIntervention. 2020 Feb 20;15(14):1240-1247
pubmed: 31763985
Eur Heart J. 2022 Feb 12;43(7):561-632
pubmed: 34453165
Nat Rev Cardiol. 2012 May 01;9(8):454-63
pubmed: 22547171
N Engl J Med. 2010 Oct 21;363(17):1597-607
pubmed: 20961243
N Engl J Med. 2016 Apr 28;374(17):1609-20
pubmed: 27040324
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
Circ Cardiovasc Interv. 2021 Jan;14(1):e009407
pubmed: 33430603
J Interv Cardiol. 2016 Aug;29(4):370-4
pubmed: 27240558
Catheter Cardiovasc Interv. 2021 Jun 1;97(7):E982-E991
pubmed: 32966682
JACC Cardiovasc Interv. 2019 Sep 23;12(18):1796-1807
pubmed: 31473236
Eur J Cardiothorac Surg. 2015 Feb;47(2):e47-53
pubmed: 25473031
Eur Heart J Cardiovasc Imaging. 2014 Dec;15(12):1324-32
pubmed: 25187618
Circulation. 2009 Mar 17;119(10):e235-40
pubmed: 19228822
Expert Rev Med Devices. 2019 Feb;16(2):81-87
pubmed: 30501446
JACC Cardiovasc Interv. 2021 Jan 25;14(2):115-134
pubmed: 33478630
Circulation. 2013 Mar 26;127(12):1300-7
pubmed: 23443735
Clin Res Cardiol. 2015 Apr;104(4):351-62
pubmed: 25388650
Catheter Cardiovasc Interv. 2021 Nov 1;98(5):E768-E779
pubmed: 33857355
Circ Arrhythm Electrophysiol. 2021 Jan;14(1):e009028
pubmed: 33306415
Eur Heart J. 2014 Jun 21;35(24):1599-607
pubmed: 24179072
EuroIntervention. 2010 Sep;6(4):475-84
pubmed: 20884435
Front Cardiovasc Med. 2018 Jul 03;5:85
pubmed: 30018969
J Electrocardiol. 2018 May - Jun;51(3):416-421
pubmed: 29530523
Circulation. 2007 Mar 13;115(10):1306-24
pubmed: 17322457